ASSESSMENT OF CARDIOTOXIC SIDE EFFECTS IN THE ADMINISTRATION OF ORGANOTIN COMPOUNDS AT THE PRECLINICAL STAGE OF THE STUDY

Abstract

The most important task of preclinical research of promising candidates for antitumor drugs is to assess the safety of their use. The study of the cardiotoxicity of organotin compounds (OOS) dimethyltin bis (3,5-di-tert-butyl-4-hydroxy- phenylthiolate) (Me3) and (3,5-di-tert-butyl-4-hydroxyphenylthiolate) triphenyltin (Me5) was carried out with a single intragastric administration at the maximum tolerated dose (MTD) in an experiment on 30 Wistar rats (female) weighing 190-210gr. According to the results of pathomorphological studies and changes in the activity of marker blood enzymes (CK - creatine kinase (EC 2.7.3.2), LDH - lactate dehydrogenase (EC 1.1.1.27), AsAt - aspartate aminotransferase (EC 2.6.1.1), AlAt - alanine aminotransferase (EC 2.6.1.2)), morpho-functional changes were characterized as potentially reversible 14 days after administration of the substances.